Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
Top Cited Papers
- 28 November 2014
- journal article
- review article
- Published by Elsevier BV in Trends in Molecular Medicine
- Vol. 21 (1), 24-33
- https://doi.org/10.1016/j.molmed.2014.10.009
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- Structure and Interactions of the Human Programmed Cell Death 1 Receptor*Journal of Biological Chemistry, 2013
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Tumor-infiltrating NY-ESO-1–specific CD8 + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancerProceedings of the National Academy of Sciences of the United States of America, 2010
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProceedings of the National Academy of Sciences of the United States of America, 2010
- Human prostate‐infiltrating CD8+ T lymphocytes are oligoclonal and PD‐1+The Prostate, 2009
- Crystal structure of the complex between programmed death-1 (PD-1) and its ligand PD-L2Proceedings of the National Academy of Sciences of the United States of America, 2008
- The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptorsProceedings of the National Academy of Sciences of the United States of America, 2008
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell ResponsesImmunity, 2007
- Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+T lymphocytes are prognostic factors of human ovarian cancerProceedings of the National Academy of Sciences of the United States of America, 2007